Auriga Laboratories Inc has announced the launch of Extendryl® PEM and Extendryl® GCP. The two new products will be prescribed in the treatment of cough, cold and allergy symptoms. The company intends to strengthen the Extendryl product line and the product launch appears to be timed to coincide with the start of the Spring allergy season.

Sun Pharmaceutical Industries has received FDA approval for its Abbreviated New Drug Application (ANDA) for the generic version of Forest Laboratories’ Tessalon (benzonatate) capsule. Tessalon capsules are used in treating cough caused by common cold, pneumonia and other lung infections. According to Sun Pharma, the annual US sales of the brand and generic Tessalon are approximately $40 million.